-- Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q2 Revenue $6.1M, vs. Street Est of $4.5M
4:23PM ET 5/12/2022 MT Newswires...
Quotes Snapshot > APDN
Applied DNA Sciences Inc APDN:NASDAQ
Last Price$1.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
Today's Change+0.16(12.90%)
Bid (Size)$1.35 (8)
Ask (Size)$1.40 (9)
Day Low / High$1.31 - 1.45
Volume17.3 K
Read more news Recent News
Applied DNA Sciences Unit Wins COVID-19 Testing Services Contract From NYC Client
10:33AM ET 4/06/2022 MT NewswiresApplied DNA Sciences (APDN) said Wednesday an undisclosed New York City-based investment management firm awarded the company's Applied DNA Clinical Labs...
--HC Wainwright Adjusts Applied DNA Sciences' Price Target to $6 from $8, Maintains Buy Rating
12:33PM ET 2/11/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
-- Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $4.2M, vs. Street Est of $4.02M
4:08PM ET 2/10/2022 MT Newswires...
View all Commentary and Analysis
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript
11:37PM ET 5/13/2022 Seeking AlphaApplied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
5:25PM ET 5/12/2022 ZacksApplied DNA Sciences (APDN) delivered earnings and revenue surprises of 6.67% and 32.19%,...
Applied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript
6:58PM ET 2/10/2022 Seeking AlphaFlora Ready To Grow Like A Weed
2:43PM ET 1/03/2022 Seeking AlphaCompany Profile
Business DescriptionApplied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. Its proprietary platform produces large quantities of DNA for use in nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets (Biotherapeutic Contract Research and Manufacturing) and for supply chain security, anti-counterfeiting and anti-theft technology purposes. The company was founded in 1983 and is headquartered in Stony Brook, NY. View company web site for more details
| Address | 50 Health Sciences Drive Stony Brook, New York 11790 |
| Phone | +1.631.240.8800 |
| Number of Employees | 59 |
| Recent SEC Filing | 05/12/2022 10-Q |
| Chairman, President & Chief Executive Officer | James A. Hayward |
| Chief Operating Officer | Judy Murrah |
| Chief Financial Officer & Controller | Beth M. Jantzen |
| Associate Director-Production | Frank Cipriani |
Company Highlights
| Price Open | $1.45 |
| Previous Close | $1.24 |
| 52 Week Range | $1.08 - 8.10 |
| Market Capitalization | $10.5 M |
| Shares Outstanding | 7.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.91 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.9 M |
| Net Profit Margin | -122.64% |
| Return on Equity | -105.72% |
Analyst Ratings as of 02/12/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |